Sarepta Therapeutics Inc is a biotechnology company focused on treating rare, infectious, and other diseases. It targets a broad range of diseases while focusing on the rapid development of its drug candidates. Sarepta's involves proprietary RNA-targeted technology platforms to be used for developing novel pharmaceutical products to treat a broad range of diseases and address key unmet medical needs. The company uses third-party contractors to manufacture its product candidates. Majority of company's product candidates are at an early stage of development.
1980
1.4K+
LTM Revenue $2.1B
LTM EBITDA $218M
$2.6B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Sarepta Therapeutics has a last 12-month revenue (LTM) of $2.1B and a last 12-month EBITDA of $218M.
In the most recent fiscal year, Sarepta Therapeutics achieved revenue of $1.9B and an EBITDA of $317M.
Sarepta Therapeutics expects next 12-month revenue of XXX   and NTM EBITDA of XXX
See Sarepta Therapeutics valuation multiples based on analyst estimatesLTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
---|---|---|---|---|---|---|
Revenue | $2.1B | XXX | $1.9B | XXX | XXX | XXX |
Gross Profit | $1.7B | XXX | $1.6B | XXX | XXX | XXX |
Gross Margin | 82% | XXX | 83% | XXX | XXX | XXX |
EBITDA | $218M | XXX | $317M | XXX | XXX | XXX |
EBITDA Margin | 10% | XXX | 17% | XXX | XXX | XXX |
EBIT | $21.4M | XXX | $218M | XXX | XXX | XXX |
EBIT Margin | 1% | XXX | 11% | XXX | XXX | XXX |
Net Profit | -$48.9M | XXX | $235M | XXX | XXX | XXX |
Net Margin | -2% | XXX | 12% | XXX | XXX | XXX |
Net Debt | XXX | XXX | $34.1M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of July 2, 2025, Sarepta Therapeutics's stock price is $18.
Sarepta Therapeutics has current market cap of $1.7B, and EV of $2.6B.
See Sarepta Therapeutics trading valuation dataEV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
---|---|---|---|---|---|---|
$2.6B | $1.7B | XXX | XXX | XXX | XXX | $-0.80 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of July 2, 2025, Sarepta Therapeutics has market cap of $1.7B and EV of $2.6B.
Sarepta Therapeutics's trades at 1.3x EV/Revenue multiple, and 8.1x EV/EBITDA.
Equity research analysts estimate Sarepta Therapeutics's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Sarepta Therapeutics has a P/E ratio of -35.6x.
See valuation multiples for Sarepta Therapeutics and 12K+ public compsLTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
---|---|---|---|---|---|---|
Market cap (current) | $1.7B | XXX | $1.7B | XXX | XXX | XXX |
EV (current) | $2.6B | XXX | $2.6B | XXX | XXX | XXX |
EV/Revenue | 1.2x | XXX | 1.3x | XXX | XXX | XXX |
EV/EBITDA | 11.7x | XXX | 8.1x | XXX | XXX | XXX |
EV/EBIT | 119.5x | XXX | 11.7x | XXX | XXX | XXX |
EV/Gross Profit | 1.5x | XXX | n/a | XXX | XXX | XXX |
P/E | -35.6x | XXX | 7.4x | XXX | XXX | XXX |
EV/FCF | -5.3x | XXX | -7.3x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialSarepta Therapeutics's last 12 month revenue growth is 9%
Sarepta Therapeutics's revenue per employee in the last FY averaged $1.4M, while opex per employee averaged $1.0M for the same period.
Sarepta Therapeutics's rule of 40 is -27% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Sarepta Therapeutics's rule of X is 34% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Sarepta Therapeutics and other 12K+ public compsLTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
---|---|---|---|---|---|---|
Revenue Growth | 9% | XXX | 10% | XXX | XXX | XXX |
EBITDA Margin | 10% | XXX | 17% | XXX | XXX | XXX |
EBITDA Growth | 79% | XXX | n/a | XXX | XXX | XXX |
Rule of 40 | -27% | XXX | 26% | XXX | XXX | XXX |
Bessemer Rule of X | XXX | XXX | 34% | XXX | XXX | XXX |
Revenue per Employee | XXX | XXX | $1.4M | XXX | XXX | XXX |
Opex per Employee | XXX | XXX | $1.0M | XXX | XXX | XXX |
S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
R&D Expenses to Revenue | XXX | XXX | 42% | XXX | XXX | XXX |
Opex to Revenue | XXX | XXX | 72% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
EV/Revenue | EV/EBITDA | |||||
---|---|---|---|---|---|---|
2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Sarepta Therapeutics acquired XXX companies to date.
Last acquisition by Sarepta Therapeutics was XXXXXXXX, XXXXX XXXXX XXXXXX . Sarepta Therapeutics acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiplesAcquired Company | EV | EV/Revenue | EV/EBITDA |
---|---|---|---|
XXXXXXXXX | XXX | XXX | XXX |
XXXXXXXXX | XXX | XXX | XXX |
XXXXXXXXX | XXX | XXX | XXX |
XXXXXXXXX | XXX | XXX | XXX |
XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free TrialWhen was Sarepta Therapeutics founded? | Sarepta Therapeutics was founded in 1980. |
Where is Sarepta Therapeutics headquartered? | Sarepta Therapeutics is headquartered in United States of America. |
How many employees does Sarepta Therapeutics have? | As of today, Sarepta Therapeutics has 1.4K+ employees. |
Who is the CEO of Sarepta Therapeutics? | Sarepta Therapeutics's CEO is Mr. Douglas S. Ingram,Esq.. |
Is Sarepta Therapeutics publicy listed? | Yes, Sarepta Therapeutics is a public company listed on NAS. |
What is the stock symbol of Sarepta Therapeutics? | Sarepta Therapeutics trades under SRPT ticker. |
When did Sarepta Therapeutics go public? | Sarepta Therapeutics went public in 1997. |
Who are competitors of Sarepta Therapeutics? | Similar companies to Sarepta Therapeutics include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
What is the current market cap of Sarepta Therapeutics? | Sarepta Therapeutics's current market cap is $1.7B |
What is the current revenue of Sarepta Therapeutics? | Sarepta Therapeutics's last 12 months revenue is $2.1B. |
What is the current revenue growth of Sarepta Therapeutics? | Sarepta Therapeutics revenue growth (NTM/LTM) is 9%. |
What is the current EV/Revenue multiple of Sarepta Therapeutics? | Current revenue multiple of Sarepta Therapeutics is 1.2x. |
Is Sarepta Therapeutics profitable? | Yes, Sarepta Therapeutics is EBITDA-positive (as of the last 12 months). |
What is the current EBITDA of Sarepta Therapeutics? | Sarepta Therapeutics's last 12 months EBITDA is $218M. |
What is Sarepta Therapeutics's EBITDA margin? | Sarepta Therapeutics's last 12 months EBITDA margin is 10%. |
What is the current EV/EBITDA multiple of Sarepta Therapeutics? | Current EBITDA multiple of Sarepta Therapeutics is 11.7x. |
What is the current FCF of Sarepta Therapeutics? | Sarepta Therapeutics's last 12 months FCF is -$483M. |
What is Sarepta Therapeutics's FCF margin? | Sarepta Therapeutics's last 12 months FCF margin is -23%. |
What is the current EV/FCF multiple of Sarepta Therapeutics? | Current FCF multiple of Sarepta Therapeutics is -5.3x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.